Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Kent based Founder operating in the Pharmaceutical space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Yue Xiong
Co-Founder and Chief Scientific Officer of Cullgen
Dr. Yue Xiong, PhD is a Director and Member of Scientific Advisory Board at Cullgen Inc. Dr. Xiong was awarded Pew Scholar Award (1995), American Cancer Society Junior Faculty Research Award (1995), AACR-Gertrude B. Elion Cancer Research Awards (1999), UNC Hettleman Award for Scholarly Achievement (1999), UNC Battle Distinguished Cancer Research Award (2011), Elected Fellow, American Association for Advancement of Science (2012). Dr. Xiong has published more than 160 research papers in peer-reviewed publication and granted two US patents. After completing a Ph.D. Postdoctoral fellowship at Cold Spring Harbor Lab, since 1993, Dr. Xiong joined Department of Biochemistry & Biophysics at University of North Carolina at Chapel Hill as a William R. Kenan Professor. Dr. Xiong finished his undergraduate at Fudan University in 1982 and Ph.D from University of Rochester in 1989.
Follow Yue Xiong:
About Cullgen: Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Jian Jin
Co-Founder of Cullgen
Follow Jian Jin:
About Cullgen, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai: Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Andrew McElroy
Co-Founder & Strategic Project Manager of Exvastat
Andrew McElroy is the CEO, Director & Founder of EligoChem & he attended University of Cambridge in 1977.
Follow Andrew McElroy:
About EligoChem, Exvastat, The Research Network: Exvastat is an innovative, preclinical-stage pharmaceutical company.
Edward Crawley
Director / Board Member & Co-Founder of ProterixBio
Follow Edward Crawley:
About : ProterixBio engages in developing innovative products to transform the management of chronic diseases.
Edward Crawley
Director / Board Member & Co-Founder of ProterixBio
Follow Edward Crawley:
About : ProterixBio engages in developing innovative products to transform the management of chronic diseases.
Hector F. DeLuca
President and Chief Executive Officer, Founder of Deltanoid Pharmaceuticals
Hector F. DeLuca, is a founder of Deltanoid Pharmaceuticals, Inc. and is recognized as a world leader in vitamin D chemistry, biochemistry and medicine, and has nearly 820 filed and active patents on his technologies. The majority of commercially-developed vitamin D analogs have originated in Professor DeLuca’s university lab. Prior to establishing Deltanoid, Dr. DeLuca was involved in the development of eight drugs marketed worldwide with over $10 billion in worldwide sales, including Alfarol®, Zemplar®, Rocaltrol®, Hectorol® and several others. Dr. DeLuca has been a successful entrepreneur involved in the creation of the publicly held pharmaceutical firm Bone Care International (NASDAQ:BCII) that was later acquired by Genzyme/Sanofi. He also was a founder of Tetrionics, sold to SAFC. He also serves on the board of Kegonsa Capital Partners. Because of his expertise in the field of vitamin D, Dr. DeLuca has developed contacts with many major pharmaceutical companies world-wide, and has served as a consultant to many firms. Professor DeLuca was a faculty member in the Department of Biochemistry for 52 years, and served for 30 years as Chairman of that department. He continues to maintain an active research program as an Emeritus Professor. He received his PhD in biochemistry from the University of Wisconsin-Madison, and honorary degrees of medicine from the University of Colorado, the Medical College of Wisconsin, the Karolinska Institute, Stockholm, and Queen’s University of Canada.
Follow Hector F. DeLuca:
About Deltanoid Pharmaceuticals: Deltanoid Pharmaceuticals Inc. is a privately funded biopharmaceutical company.
Peter Widdowson
Founder & CEO of Quethera
Peter Widdowson has over 30 years of drug discovery experience during which he has worked on a number of small molecule, protein and gene therapy approaches to managing disease. He has a background in researching therapies for indications as diverse as ophthalmic, neurological and psychiatric disorders, type-2 diabetes, oncology, gastrointestinal motility disorders and inflammatory conditions encompassing inflammatory bowel disease and rheumatoid arthritis. He has held a number of senior scientific roles within Servier (Research Group Leader), AstraZeneca (Senior Scientist and Project Research Manager), Pfizer (Senior Scientist and Project Research Manager), OSI Pharmaceuticals (Director of Pharmacology) and most recently, whilst Head of Preclinical Development at Oxford BioMedica was responsible for overseeing and managing the development of three lentiviral vector gene therapies for wet age-related macular degeneration, Stargardt disease and Usher 1B syndrome which are all currently in Phase I/II clinical development. Dr. Widdowson has experience in all aspects of preclinical and early stage development from animal model proof-of-concept studies to clinical trial design and biomarker identification. Widdowson holds a Bachelor of Science degree in human Physiology from Newcastle University and a PhD in Neuropharmacology from Manchester University.
Follow Peter Widdowson:
About Ikarovec, Quethera: Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases.
John Carroll
President & Founder of Vita-Stat
John is a nationally recognized management and technology consultant with more than 30 years of experience designing, developing, and managing government systems and private sector projects. He is credited with building the technical infrastructure of ACCUflo, a complete point of care solution specializing in the accurate tracking of resident healthcare data. Prior to founding Vita-Stat, he served as Vice President of Online Systems Development for Stored Value Systems where he is credited as the lead designer of the online electronic gift certificate and merchandise return stored value card system currently used by major retailers worldwide. He holds a Bachelor of Science degree in Computer Science and Minor in Mathematics from Eastern Kentucky University and earned an MBA from Bellarmine University.
Follow John Carroll:
About Glennis Solutions, Vita-Stat: Vita-Stat is one of the original innovators of electronic medication, treatment, and care management solutions to optimize and error proof.
Alfredo Boni
Founder & President of Creabilis
Alfredo Boni was the CEO of a large service company, Boni S.p.A, which has operated since 1964 across Europe within many industries in the field of general maintenance, cleaning and sterilization. He was also the founder of a consortium of more than 150 companies devoted to global service for various institutions including hospitals. His industrial, financial and administrative experience in founding and acquiring companies and his entrepreneurial spirit are now being devoted to the world of biotechnology.
Follow Alfredo Boni:
About Creabilis: Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.
Larry Horn
Co-Founder of TNG Pharmaceuticals
MBA – Co-Founder, has over 15 years sales and operations management experience. He also has extensive experience managing mergers and acquisitions, projects and integration.
Follow Larry Horn:
About TNG Pharmaceuticals: TNG Pharmaceuticals, a Louisville, KY based company is focused on the research and development of our patented vaccine, FlyVax.
